MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Orforglipron Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Orforglipron (LY3502970) is a first-in-class oral, non-peptide GLP-1 receptor agonist from Eli Lilly, developed for obesity and type 2 diabetes. As a small molecule rather than a peptide, it survives digestion and works as a once-daily tablet taken with or without food. It activates the GLP-1 receptor through a Gs-biased, partial-agonist mechanism that boosts cyclic AMP signaling, increasing glucose-dependent insulin release, slowing gastric emptying, and reducing appetite (PMID 37344954). Clinical dosing relies on a slow titration that begins at 1 mg/day and climbs every four weeks toward maintenance doses of 6, 12, 24, or 36 mg/day. In the Phase 3 ATTAIN-1 trial, 72 weeks of treatment cut body weight by 7.8% to 12.4% across doses versus 2.1% with placebo. Gastrointestinal effects are the main tolerability issue and are managed by titrating slowly. Orforglipron is investigational and is not yet FDA- or EMA-approved.
Reconstitute: Add 1.5 mL bacteriostatic water → 20 mg/mL concentration.
Typical dose: 1-36 mg once daily orally (titrated)
Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg (200 mcg) on a U-100 insulin syringe.
Storage: Clinically supplied as an oral tablet stored at room temperature. For the educational reconstitution model only: lyophilized powder kept frozen at −20 °C; reconstituted solution refrigerated at 2-8 °C, protected from light, and used within roughly 4 weeks.
Half-life: Roughly 24-36 hours after a single dose, rising to about 48-68 hours at steady state — long enough to support once-daily dosing [1][2].
Route: Oral once-daily tablet in the clinic (with or without food); the subcutaneous reconstitution figures here are an educational model only.
Status: Investigational — not approved by the FDA or EMA; Phase 3 complete and under regulatory review [5][6].
About Orforglipron
Orforglipron (LY3502970) is an oral, non-peptide small-molecule GLP-1 receptor agonist — a once-daily tablet engineered by Eli Lilly to deliver injectable-grade incretin pharmacology without a needle [1][6]. Clinically, and in every published trial, it is swallowed as a tablet once daily with or without food; the subcutaneous reconstitution figures below are an educational measurement reference only, not the real-world route. We model it as a vial-and-bacteriostatic-water protocol purely to keep this page consistent with the rest of the site.\n\nThe defining feature of the Orforglipron dosage protocol is a slow, four-week-interval titration. Phase 3 programs (ATTAIN for obesity, ACHIEVE for type 2 diabetes) started participants at 1 mg once daily and stepped the dose up gradually — through 3 mg, 6 mg, and 12 mg — toward maintenance doses of 6, 12, 24, or 36 mg/day, depending on the trial and tolerance [3][4][5]. This gradual escalation is the main lever for limiting nausea, vomiting, and other gastrointestinal effects.\n\nThis guide models a 30 mg vial reconstituted with 1.5 mL of bacteriostatic water (20 mg/mL) so that, hypothetically, doses map onto a U-100 insulin syringe: 1 mg ≈ 5 units, 3 mg ≈ 15 units, 6 mg ≈ 30 units, and 12 mg ≈ 60 units. Because oral GLP-1 doses are measured in milligrams (far larger than typical injectable peptide doses in micrograms), the highest maintenance dose, 36 mg, would equal about 180 units and is shown only to illustrate why orforglipron is, in reality, a pill.\n\nFrequency: Once daily, at a consistent time. Orforglipron is investigational and is NOT FDA- or EMA-approved; this page is for educational purposes only.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 1.5 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inner wall of the 30 mg orforglipron vial; avoid spraying the stream directly onto the powder and do not shake vigorously.
Gently swirl or roll the vial until the solution is completely clear; the result is a 20 mg/mL concentration, so each U-100 insulin-syringe unit holds 200 mcg.
Store refrigerated at 2-8 °C and draw the prescribed units per dose (1 mg ≈ 5 units, 3 mg ≈ 15 units, 6 mg ≈ 30 units, 12 mg ≈ 60 units; 36 mg ≈ 180 units, which exceeds one syringe and would be split).
Educational note: orforglipron is clinically taken ORALLY as a once-daily tablet — these subcutaneous reconstitution figures are a measurement reference only and are not a validated route of administration.
Interactive Orforglipron Syringe Calculator
Currently visualizing the 30 mg vial reconstituted with 1.5 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 30mg dry powder in 1.5mL water yields 20.00 mg/mL. To evaluate a 250mcg dose, pull to 1.3 units (1 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Weeks 1-4 — initiation (1 mg/day) | 1000 mcg (1 mg) | 5 units (0.05 mL) |
| Weeks 5-8 — first step-up (3 mg/day) | 3000 mcg (3 mg) | 15 units (0.15 mL) |
| Weeks 9-12 — lowest Phase 3 maintenance (6 mg/day) | 6000 mcg (6 mg) | 30 units (0.30 mL) |
| Week 13+ — common maintenance (12 mg/day; trials titrate up to 24-36 mg) | 12000 mcg (12 mg) | 60 units (0.60 mL) |
Administration guidelines: Refer to guidelines | 1.5 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 30 mg vial.
Peptide Vials (Orforglipron, 30 mg each):
- check8 weeks at 6 mg/day ≈ 12 vials (336 mg total)
- check12 weeks at 12 mg/day ≈ 34 vials (1,008 mg total)
- check16 weeks at 36 mg/day ≈ 135 vials (4,032 mg total) — the very high count illustrates why orforglipron is dosed as an oral tablet, not an injection
Insulin Syringes (U-100):
- checkOnce-daily dosing: 7 syringes per week
- check8 weeks ≈ 56 syringes; 12 weeks ≈ 84 syringes; 16 weeks ≈ 112 syringes
- checkHigh maintenance doses (36 mg ≈ 180 units) exceed one syringe and would require two injections, doubling the count
Bacteriostatic Water (30 mL bottles): Use 1.5 mL per vial for reconstitution.
- check8 weeks (~12 vials) ≈ 18 mL — about 1 bottle
- check12 weeks (~34 vials) ≈ 51 mL — about 2 bottles
- check16 weeks (~135 vials) ≈ 203 mL — about 7 bottles
Alcohol Swabs: wipe the vial septum and the (modeled) injection site before each use.
- checkAbout 2 swabs per dose (vial top plus injection site) ≈ 14 swabs per week
- check8 weeks ≈ 112 swabs; 12 weeks ≈ 168 swabs; 16 weeks ≈ 224 swabs
- checkKeep a surplus box on hand to maintain sterile technique
Mechanism of Action (MOA)
Orforglipron is a small-molecule, non-peptide agonist of the glucagon-like peptide-1 receptor (GLP-1R), the same receptor targeted by injectable peptides like semaglutide and liraglutide [1][6]. Because it is a synthetic chemical rather than a peptide, it resists enzymatic breakdown in the gastrointestinal tract and is absorbed well enough to work as an oral tablet — the central advantage that distinguishes it from injectable incretins and from oral semaglutide, which requires a permeation enhancer and strict fasting conditions [6].\n\nMechanistically, orforglipron binds an allosteric transmembrane pocket of the GLP-1 receptor distinct from where the native peptide docks. It stabilizes an active receptor conformation that couples efficiently to Gs proteins and drives intracellular cyclic AMP (cAMP) accumulation, while recruiting comparatively little β-arrestin. This \"Gs-biased\" partial-agonist profile is thought to favor the metabolic signaling that produces clinical benefit while potentially reducing receptor desensitization seen with full agonists [1][6]. Downstream, GLP-1R activation enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release, slows gastric emptying, and acts on hypothalamic appetite centers to reduce hunger and energy intake — together driving both glycemic control and weight loss [3][4][5].\n\nPharmacokinetics support a once-daily tablet. After a single oral dose, the mean elimination half-life is roughly 24 to 36 hours, lengthening to approximately 48 to 68 hours at steady state with repeated dosing, and exposure is approximately dose-proportional [1][2][6]. Peak plasma concentrations are reached about 2 to 4 hours after dosing, and oral bioavailability is on the order of 30 to 40% [6]. Critically, food has minimal effect on systemic exposure, so — unlike oral semaglutide — orforglipron can be taken with or without meals and without a water-volume restriction, simplifying real-world use [6].\n\nBecause the GLP-1 effect on the gut is dose-related, the clinical programs rely on slow titration. Participants began at 1 mg once daily and increased the dose at roughly four-week intervals toward their assigned maintenance dose (6, 12, 24, or 36 mg), which allows the gastrointestinal system to adapt and limits nausea and vomiting [3][4][5]. Pharmacodynamic markers confirm target engagement at these doses: early-phase studies documented delayed gastric emptying, lowered fasting glucose, and meaningful weight reduction within four weeks [1][2].\n\nThe real-world route is oral. The subcutaneous reconstitution scheme on this page is an educational measurement convention used across this site, not a clinically validated delivery method. Orforglipron is investigational and is not approved by any major regulator [5][6].
Clinical Trial Efficacy Highlights
- starPratt and colleagues (2023, Diabetes, Obesity and Metabolism) reported the Phase 1a single- and multiple-ascending-dose study in healthy adults: orforglipron showed approximately dose-proportional pharmacokinetics, a single-dose half-life of 24.6-35.3 hours (rising to 48.1-67.5 hours at steady state), delayed gastric emptying, lowered fasting glucose, and body-weight reductions of up to 5.4 kg at four weeks versus 2.4 kg with placebo, with mostly gastrointestinal adverse events [1].
- starPratt and colleagues (2023, Diabetes, Obesity and Metabolism) ran the companion Phase 1b multiple-ascending-dose study in people with type 2 diabetes, confirming the once-daily pharmacokinetic profile and showing reductions in fasting glucose and HbA1c with a tolerability pattern consistent with injectable GLP-1 receptor agonists [2].
- starFrias and colleagues (2023, The Lancet) conducted a 26-week Phase 2 dose-response trial in type 2 diabetes (doses from 3 mg to 45 mg once daily versus placebo and dulaglutide); orforglipron produced dose-dependent HbA1c reductions of up to roughly 2.1% and substantial weight loss, establishing efficacy comparable to or exceeding an injectable comparator [3].
- starWharton and colleagues (2023, New England Journal of Medicine) reported a Phase 2 obesity trial in 272 adults randomized to 12, 24, 36, or 45 mg or placebo: at 36 weeks mean body-weight change ranged from −9.4% to −14.7% with orforglipron versus −2.3% with placebo, with gastrointestinal events most common during titration [4].
- starIn the Phase 3 ATTAIN-1 trial (Wharton, Aronne, et al., 2025, New England Journal of Medicine), 72 weeks of orforglipron at 6, 12, and 36 mg produced mean weight reductions of 7.8%, 9.3%, and 12.4% respectively versus 2.1% with placebo, meeting the primary endpoint with a safety profile consistent with other GLP-1 receptor agonists [5].
- starATTAIN-1 also quantified tolerability: the most common adverse events were gastrointestinal — nausea (28.9-35.9% across doses), constipation (21.7-29.8%), diarrhea (21.0-23.1%), and vomiting (13.0-24.0%) — versus much lower rates on placebo, with treatment discontinuation due to adverse events of 5.3%, 7.9%, and 10.3% at the 6, 12, and 36 mg doses versus 2.7% with placebo [5][7].
- starA 2026 comprehensive review (Kansakar et al., International Journal of Molecular Sciences) consolidated the pharmacology: orforglipron is a non-peptide, Gs-biased partial GLP-1R agonist with a half-life of about 24-36 hours, Tmax of 2-4 hours, oral bioavailability near 30-40%, and minimal food effect, bridging injectable incretin efficacy with oral convenience [6].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningGastrointestinal effects are the most common and are dose-related: nausea, vomiting, diarrhea, and constipation, generally mild-to-moderate and concentrated during the titration period [4][5].
- warningIn Phase 3 ATTAIN-1, dose-by-dose rates were nausea 28.9-35.9%, constipation 21.7-29.8%, diarrhea 21.0-23.1%, and vomiting 13.0-24.0%, all substantially higher than placebo [5][7].
- warningTreatment discontinuation due to adverse events rose with dose — about 5.3% at 6 mg, 7.9% at 12 mg, and 10.3% at 36 mg versus 2.7% with placebo — underscoring the trade-off between higher doses and tolerability [5][7].
- warningSlow titration (starting at 1 mg and stepping up roughly every four weeks) is the principal strategy to limit gastrointestinal effects; skipping steps or escalating too quickly markedly increases nausea and vomiting [3][4].
- warningAs a class, GLP-1 receptor agonists carry risks of dehydration from vomiting or diarrhea, gallbladder events (cholelithiasis), and pancreatitis; hypoglycemia risk increases when combined with insulin or sulfonylureas, which may require dose reductions of those agents.
- warningClass labeling for GLP-1 receptor agonists includes a contraindication in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2; use in pregnancy or breastfeeding is not recommended.
- warningMild, generally transient elevations in liver transaminases have been reported in some orforglipron study participants, warranting awareness and monitoring; long-term safety is still being characterized in ongoing trials.
- warningRegulatory/research status: orforglipron is NOT approved by the FDA or EMA and is investigational; it is under regulatory review following Phase 3. This page is educational only, and the subcutaneous reconstitution model is not a real or recommended route of administration.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Orforglipron dosage?expand_more
Orforglipron is taken once daily by mouth and is titrated slowly. Phase 3 trials started participants at 1 mg/day and stepped the dose up at roughly four-week intervals (for example 1 → 3 → 6 → 12 mg) toward maintenance doses of 6, 12, 24, or 36 mg/day, depending on the trial and tolerance. In the ATTAIN-1 obesity trial the maintenance doses were 6, 12, and 36 mg/day. There is no approved label yet because the drug is still investigational, so any specific dose is set within a clinical trial or future prescribing information, not by this educational page.
Is Orforglipron FDA approved?expand_more
No. As of mid-2026 orforglipron is investigational and is not approved by the FDA or the EMA. After positive Phase 3 results in obesity (ATTAIN) and type 2 diabetes (ACHIEVE), Eli Lilly initiated global regulatory submissions, so the compound is under review but not yet authorized. Treat all information here as educational only, not medical advice.
What is the Orforglipron half life?expand_more
The mean elimination half-life is roughly 24 to 36 hours after a single oral dose, lengthening to about 48 to 68 hours at steady state with repeated daily dosing. This long half-life, combined with a Tmax of about 2 to 4 hours, is what allows orforglipron to be dosed just once daily.
How is Orforglipron administered?expand_more
In the clinic it is a once-daily oral tablet that can be taken with or without food and without a water-volume restriction, because food has minimal effect on its absorption. This is a key practical advantage over oral semaglutide. The subcutaneous reconstitution figures on this page are an educational measurement model only and do not reflect a real or recommended route.
How would you reconstitute Orforglipron for the educational model?expand_more
For this site's modeling convention only, draw 1.5 mL of bacteriostatic water and add it slowly to a 30 mg vial, swirling gently until clear. That yields a 20 mg/mL solution where each U-100 insulin-syringe unit holds 200 mcg (so 1 mg ≈ 5 units, 6 mg ≈ 30 units, 12 mg ≈ 60 units). Remember that orforglipron is actually an oral tablet; this reconstitution is illustrative, not a clinical method.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Orforglipron, plus the universal dosing calculator.
Academic References & Study Citations
Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023;25(9):2634-2641. View Scientific Paper →
Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab. 2023;25(9):2642-2649. View Scientific Paper →
Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472-483. View Scientific Paper →
Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389(10):877-888. View Scientific Paper →
Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-1806. View Scientific Paper →
Kansakar U, Jankauskas SS, Pande S, Mone P, Varzideh F, Santulli G. Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes. Int J Mol Sci. 2026;27(3):1409. View Scientific Paper →
Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine (press release, 2025). View Scientific Paper →
ClinicalTrials.gov. A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1). NCT05869903. View Scientific Paper →